Lawmakers in New Hampshire advanced a bill Friday that would make releasing large numbers of balloons a crime.
BMO Capital lowered the firm’s price target on Morningstar (MORN) to $370 from $387 but keeps an Outperform rating on the shares. The ...
Hosted on MSN17d
Kiniksa issues updates on abiprubart, KPL-387, mavrilimumabKiniksa (NASDAQ:KNSA) plans to initiate a Phase 2/3 clinical study of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026.It added that Phase 1 ...
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results